MedPage Today3d
FDA Says Compounded Tirzepatide Must Exit the Market
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
FiercePharma3d
FDA reaffirms decision to erase Eli Lilly's tirzepatide from shortage list, halting future flow of knockoffs
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...
HME News1h
FDA approves GLP-1 for OSA
The U.S. Food and Drug Administration announced Dec. 20 that it has approved Zepbound (tirzepatide) for the treatment of moderate to severe sleep apnea in adults with obesity to be used ...
KETV Omaha19h
FDA approves weight-loss drug Zepbound for obstructive sleep apnea
The FDA approval for sleep apnea is based on two company-sponsored ... Treatment with Zepbound, whose generic name is ...
STAT3d
Is a contrarian leader good for the FDA?
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Investing4d
Hims & Hers shares tumble as FDA resolves obesity drug shortage
The FDA's latest decision could reshape the market dynamics for obesity drugs, as compounded versions were allowed under U.S. regulations during the shortage. Hims & Hers Health's stock movement today ...
BioSpace5d
FDA Issues Warning Letters Against GLP-1 Compounders
The letters come amid the Outsourcing Facilities Association’s ongoing lawsuit against the FDA over the regulator’s decision ...
STAT5d
A key decision on compounding is expected this week
To refresh: In early October, the FDA pulled Eli Lilly’s tirzepatide off its drug shortage list after nearly two years.